Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design

A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization

(2017) Esther Drent et al.   MOLECULAR THERAPY

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

(2017) Justin Eyquem et al.   NATURE

An oxygen sensitive self-decision making engineered CAR T-cell

(2017) Alexandre Juillerat et al.   Scientific Reports

Increasing the safety and efficacy of chimeric antigen receptor T cell therapy

(2017) Hua Li et al.   Protein & Cell

Toxicities of chimeric antigen receptor T cells: recognition and management

(2016) Jennifer N. Brudno et al.   BLOOD

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

(2016) J. Krejcik et al.   BLOOD

Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits

(2016) Kole T. Roybal et al.   CELL

Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors

(2016) Leonardo Morsut et al.   CELL

Tet-On Systems For Doxycycline-inducible Gene Expression

(2016) Atze T. Das et al.   CURRENT GENE THERAPY

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

(2016) E. Drent et al.   HAEMATOLOGICA

Medical management of side effects related to CAR T cell therapy in hematologic malignancies

(2016) Manjusha Namuduri et al.   Expert Review of Hematology

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

(2016) E. Drent et al.   HAEMATOLOGICA

A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration

(2016) R. Sakemura et al.   Cancer Immunology Research

Design of chimeric antigen receptors with integrated controllable transient functions

(2016) Alexandre Juillerat et al.   Scientific Reports

The quest for spatio-temporal control of CAR T cells

(2015) Jie Sun et al.   CELL RESEARCH

CAR therapy: the CD19 paradigm

(2015) Michel Sadelain   JOURNAL OF CLINICAL INVESTIGATION

Redirection of Genetically Engineered CAR-T Cells Using Bifunctional Small Molecules

(2015) Min Soo Kim et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Remote control of therapeutic T cells through a small molecule-gated chimeric receptor

(2015) C.-Y. Wu et al.   SCIENCE

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies

(2014) Shannon L. Maude et al.   CANCER JOURNAL

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Preclinical In Vivo Modeling of Cytokine Release Syndrome Induced by ErbB-Retargeted Human T Cells: Identifying a Window of Therapeutic Opportunity?

(2013) S. J. C. van der Stegen et al.   JOURNAL OF IMMUNOLOGY

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Doxycycline Alters Metabolism and Proliferation of Human Cell Lines

(2013) Ethan Ahler et al.   PLoS One

PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

(2013) V. D. Fedorov et al.   Science Translational Medicine

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

(2011) J. N. Kochenderfer et al.   BLOOD

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

(2011) X. Wang et al.   BLOOD

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

(2011) R. J. Brentjens et al.   BLOOD

Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy

(2011) Antonio Di Stasi et al.   NEW ENGLAND JOURNAL OF MEDICINE

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

(2010) Maria R Parkhurst et al.   MOLECULAR THERAPY

Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy

(2009) M. Griffioen et al.   HAEMATOLOGICA

A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect

(2008) H. Rozemuller et al.   HAEMATOLOGICA